Anaphylaxis Checklist for Pharmacists

pdfAnaphylaxis Checklist for Pharmacists131.01 KBASCIA Anaphylaxis Checklist for Pharmacists 

  1. Dispense prescribed adrenaline (epinephrine) autoinjectors
    • Dispense prescribed adrenaline autoinjector/s and check that the dose is appropriate: 150 microgram devices for children weighing 7.5 to 20kg and 300 microgram devices for children weighing over 20kg and adults, including pregnant women. Two devices for children or adults are rebated by the PBS in Australia. No devices are currently rebated by Pharmac in New Zealand.
    • Remind the customer (patient and/or carer) to check and note the expiry date of their autoinjector/s and inform the customer of expiry reminder clubs (e.g. EpiClub).
    • Check that the patient has an ASCIA Action Plan for Anaphylaxis (RED) that should have been completed by their doctor or nurse practitioner.
    • Reinforce the need for the patient to always carry their adrenaline autoinjector and ASCIA Action Plan.
    • Check that the patient’s asthma is well managed and refer them back to their doctor or nurse practitioner if further action is required. Patients at risk of severe allergic reactions (anaphylaxis) who have asthma that is not well controlled are at increased risk of fatal anaphylaxis.
  2. Dispense non-prescribed adrenaline autoinjectors
    • Dispense adrenaline autoinjector/s to customers (patients/carers or organisations) for use in addition to prescribed devices or in first aid kits. Non-prescribed devices are not rebated by PBS or Pharmac.
    • Remind the customer to check and note the expiry date of their adrenaline autoinjector/s.
    • Check that the customer has an ASCIA First Aid Plan for Anaphylaxis (ORANGE) that should be stored with the non-prescribed device/s. These plans are available at www.allergy.org.au/anaphylaxis
  3. Provide adrenaline autoinjector advice, education and training
    • Teach the customer how to use their prescribed or non-prescribed adrenaline autoinjector/s using a trainer device. Trainer devices are available from the supplier or patient organisations (Allergy & Anaphylaxis Australia www.allergyfacts.org.au or Allergy New Zealand www.allergy.org.nz).
    • Educate the customer about correct storage of adrenaline autoinjectors, away from excessive heat or cooling. www.allergy.org.au/hp/anaphylaxis/adrenaline-autoinjector-storage-expiry-and-disposal
    • Ensure the customer understands that adrenaline is the first line treatment for anaphylaxis and that antihistamines should not be used for the treatment for anaphylaxis. If antihistamines are used to treat mild to moderate allergic reactions, only non-sedating antihistamines should be used.
  4. Be prepared for an anaphylaxis emergency
    • Train staff to recognise the signs and symptoms of anaphylaxis, how to position the patient, how to administer adrenaline autoinjectors and to phone an ambulance immediately afterwards.
    • Display ASCIA Action First Aid Plans for Anaphylaxis to assist staff in recognising and responding to an anaphylaxis emergency.

For adrenaline autoinjector supply updates check www.allergy.org.au/members/adrenaline-autoinjector-availability

© ASCIA 2020

ASCIA is the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand.
ASCIA resources are based on published literature and expert review, however, they are not intended to replace medical advice. The content of ASCIA resources is not influenced by any commercial organisations.
For more information go to www.allergy.org.au      
To donate to immunology/allergy research go to www.allergyimmunology.org.au

Content updated March 2020

Mod ASCIA Member
Donate to AIFA
go to NAS website
Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:

About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.